BARD1 Life Sciences Raises $15m for cancer tests
- BARD1 Life Sciences (BD1) raises $15M through a placement to fund development and commercialisation of its cancer diagnostic tests
- BD1 will issue 9.6M fully paid ordinary shares to new and existing institutional and sophisticated investors at $1.55 each
- Existing shareholders will be offered the opportunity to participate in a share purchase plan to raise a further $2M on the same terms as the placement
- For every two shares issued under the SPP, each investor will also entitled to one free quoted option exercisable at $2.32
- The funds will go towards commercialisation of BD1’s SubB2M programs for detection of breast and ovarian cancers, and its EXO-NET products
